An enormous growth trend is being observed in the market for biologic drugs. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
Available funding and investor support, FDA's acceleration of drug review & approvals, and a favorable regulatory landscape for orphan drug are all factors that are leading to favorable market conditions, making the biologics market an attractive for new players.
Several questions arise frequently regarding selection of the proper primary package system for a biologic/biosimilar, including:
Manager TCS, Generics Market & Asia Pacific,
Kwang Kok Li is currently the Manager for TCS, Generics Mkt & AP. She holds a bachelor's degree in chemical engineering from the National University of Singapore. She has been with West Pharmaceutical Services Singapore for the past 13 years and is involved in the technical support of drug manufacturers in the Asia Pacific region. She works closely with customers to support their packaging requirements for new drug development and addresses any technical challenges faced by the customers. Kok Li leads a team of 5 members in the AP region to establish a good scientific understanding of the packaging systems, so as to deliver insights and value-added learnings to the customers Education: She holds a bachelor's degree in chemical engineering from the National University of Singapore
© 2021 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer
Web Interface Conceived and Powered By : SCI Knowledge Interlinks